3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial
Titel:
3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial
Auteur:
Brasó-Maristany, F. Oliveira, M. Ortega, P. Tolosa Vila, M. Margeli Jurado, J. Cruz Bofill, F.J. Salvador Cejalvo, J.M. Arumi de Dios, M.A. Losada, M.J. Vidal Simon, S. Pernas Esker, S. Fan, P-D. Santhanagopal, A. Saez, O. Martinez Villacampa, G. Bayona, R. Sanchez Ferrero-Cafiero, J.M. Falato, C. Pascual, T. Prat, A.